Ovarian CancerPhase 1NCT06930755
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
A Phase 1 study testing NMS-03305293 and Topotecan in people with Ovarian Cancer, run by Nerviano Medical Sciences at 5 sites in United States.
Trial summary
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer
- What is being tested?
- NMS-03305293 and Topotecan
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 5 sitesUnited States
- Study dates
- 13 May 2026to 26 Sep 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed diagnosis of high-grade serous epithelial ovarian, fallopian tube or peritoneal cancer. Sponsor might opt to restrict enrollment to either platinum refractory, primary or secondary platinum-resistant patients based on data emerging from the trial.
- Patients must have received no more than 5 prior lines of therapy and failed all evidence based local standards of care as per Investigator judgment. Sponsor might opt to restrict prior lines of therapy to 3 in any moments, based on data emerging from the trial.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Patient must have progressed radiographically on or after their most recent line of anticancer therapy and have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (radiologically measured by the Investigator).
- Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) Grade ≤ 1 or to the baseline laboratory values as defined in the protocol
- Patients with childbearing potential must use highly effective contraception or true abstinence.
Who cannot join
- Current enrollment in another interventional clinical trial.
- Current treatment with other anticancer agents or devices.
- BReast CAncer gene (BRCA) mutation.
- Prior therapy with PARP inhibitor, outside of approved indication and schedules. Sponsor might opt to restrict prior use of PARP inhibitor (PARPi) in any moments, based on data emerging from the trial.
- Prior therapy with topoisomerase inhibitors including payloads of Antibody-Drug Conjugates (ADCs). Sponsor has the option to allow prior ADC, if not last line of treatment, prior to enrollment.
- Major surgery, other than surgery for recurrent Ovarian Cancer (OC), within 4 weeks prior to treatment start.
Show all 25Show fewer
- Patients with low-grade/borderline ovarian tumor.
- Prior anti-tumor treatment within 2 weeks prior to treatment start or 5 half-lives, whichever is shorter.
- Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow.
- Use of full-dose anticoagulants unless the INR or activated thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks before enrollment.
- Treatment with concomitant medications known to be sensitive substrates of CYP2D6 and CYP2C19 that cannot be replaced with another treatment.
- History of interstitial lung disease or relevant lung disease in the opinion of the Investigator.
- Treatment with systemic immune modulators such as corticosteroids at prednisone equivalent dose of > 10 mg/day, cyclosporine and tacrolimus or radiotherapy within 28 days before Cycle 1 Day 1.
- Pregnant women. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the screening period prior to start of study drug.
- Breast-feeding women or women planning to breast feed during the study or within 3 months after study treatment.
- Known hypersensitivity to any component of NMS-03305293 or topotecan drug formulations.
- Known active, life-threatening or clinically significant uncontrolled systemic infection (bacterial, fungal, viral including Human Immunodeficiency Virus (HIV) positivity or Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infections) requiring systemic treatment; HIV or AIDS-related illness are allowed as long as controlled more than 6 months to undetectable on anti-HIV medications.
- Patients with QTc interval ≥ 450 milliseconds or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment prior to enrollment is mandatory. If concomitant use of anti-emetics is considered essential for the care of the patients, follow instruction in this protocol.
- Known active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes or structural issues or ulcer that would impact on drug absorption.
- Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, active bleeding disorder and interstitial lung disease.
- History of long QT disorder or familial sudden death syndromes or related syndromes in the opinion of the Investigator.
- Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or cone biopsied or post curative intention in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
- Symptomatic, or untreated Central Nervous System (CNS) lesions except stable and well-controlled with no neurological symptoms; patients receiving corticosteroids to control neurological symptoms should be on stable doses for at least 14 days before study entry.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- NOTE: Other protocol defined inclusion and exclusion criteria may apply.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
- Recruiting
Tennessee Oncology
Nashville, Tennessee, 37203
- Recruiting
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
- Recruiting
Penn Medicine - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104
- Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63130
About this study
Official title: Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
- Conditions
- Ovarian Cancer
- Being tested
- NMS-03305293, Topotecan
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NMS-03305293Drug
Route of administration: Oral
TopotecanDrug
Route of administration: Intravenous
| Study group | Role | What they receive |
|---|---|---|
| NMS-03305293 and Topotecan | Experimental | NMS-03305293 will be administered orally, twice daily, on a 1-7-day schedule, in repeated 4-week cycles (i.e., 28 days). Topotecan will be administered intravenously (IV), once weekly, on Days 1, 8, and 15, of Weeks 1-3, in repeated 4-week cycles (i.e., 28 days) at 4 mg/m^2 with maximum dose of 4 mg. Receives: Drug: NMS-03305293; Drug: Topotecan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Adverse Events (AEs)
Evaluation of type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0), duration of AEs, first cycle DLT, electrocardiogram (ECG) and laboratory abnormalities and relationship of AE to study treatment
Measured: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)
Secondary outcomes (5)
Overall Response Rate (ORR)
Calculated as the proportion of evaluable patients who have achieved, as best overall response (BOR), complete response (CR) or partial response (PR) through Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Measured: From the date of first response up to data cut-off (approximately 22 months)
Duration of response (DoR)
Duration of response will be calculated from the date of either first CR or PR until the date of documented progression for patients who achieved CR or PR. Patients who died without report of progression will be considered non-events and censored at their last disease-free assessment date
Measured: From the date of first response up to data cut-off (approximately 22 months)
Progression-free survival (PFS)
Progression Free Survival will be calculated from the date of treatment initiation to the date of first documentation of disease progression, or death due to any cause, whichever occurs first
Measured: From the date of treatment initiation up to data cut-off (approximately 24 months)
Overall survival (OS)
Overall Survival will be calculated from the date of treatment initiation to the date of death due to any cause
Measured: From the date of treatment initiation up to data cut-off (approximately 24 months)
Plasma pharmacokinetic profile of NMS-03305293 and possible identified metabolites (if appropriate) after oral administration
Measured: Cycle 1 - Days 1, 2, and 5. Each cycle is 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2025
- Study start13 May 2026
- Primary completion31 May 2027 (estimated)
- Study completion26 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nerviano Medical Sciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06930755
- Sponsor's protocol ID
- PARPA-293-003
- Status last verified
- May 2026
- First submitted
- 9 Apr 2025
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer
- ClinicalTrials.gov ID
- NCT06930755
- Acronym / sponsor ID
- PARPA-293-003
- Conditions
- Ovarian Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Nerviano Medical SciencesIndustry (pharma, biotech, devices)
- Study start
- 13 May 2026 (actual)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 26 Sep 2027 (estimated)
- First posted
- 16 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NMS-03305293 and Topotecan | Experimental | Drug: NMS-03305293, Drug: TopotecanNMS-03305293 will be administered orally, twice daily, on a 1-7-day schedule, in repeated 4-week cycles (i.e., 28 days). Topotecan will be administered intravenously (IV), once weekly, on Days 1, 8, and 15, of Weeks 1-3, in repeated 4-week cycles (i.e., 28 days) at 4 mg/m^2 with maximum dose of 4 mg. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Histologically confirmed diagnosis of high-grade serous epithelial ovarian, fallopian tube or peritoneal cancer. Sponsor might opt to restrict enrollment to either platinum refractory, primary or secondary platinum-resistant patients based on data emerging from the trial.
- Patients must have received no more than 5 prior lines of therapy and failed all evidence based local standards of care as per Investigator judgment. Sponsor might opt to restrict prior lines of therapy to 3 in any moments, based on data emerging from the trial.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Patient must have progressed radiographically on or after their most recent line of anticancer therapy and have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (radiologically measured by the Investigator).
- Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) Grade ≤ 1 or to the baseline laboratory values as defined in the protocol
Key exclusion criteria (25 listed)
- Current enrollment in another interventional clinical trial.
- Current treatment with other anticancer agents or devices.
- BReast CAncer gene (BRCA) mutation.
- Prior therapy with PARP inhibitor, outside of approved indication and schedules. Sponsor might opt to restrict prior use of PARP inhibitor (PARPi) in any moments, based on data emerging from the trial.
- Prior therapy with topoisomerase inhibitors including payloads of Antibody-Drug Conjugates (ADCs). Sponsor has the option to allow prior ADC, if not last line of treatment, prior to enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NMS-03305293Route of administration: Oral | Drug | NMS-03305293 and Topotecan |
| TopotecanRoute of administration: Intravenous | Drug | NMS-03305293 and Topotecan |
Primary outcome
Number of Participants with Adverse Events (AEs)
Time frame: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)
Evaluation of type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0), duration of AEs, first cycle DLT, electrocardiogram (ECG) and laboratory abnormalities and relationship of AE to study treatment
5 secondary outcomes
Overall Response Rate (ORR)
Time frame: From the date of first response up to data cut-off (approximately 22 months)
Duration of response (DoR)
Time frame: From the date of first response up to data cut-off (approximately 22 months)
Progression-free survival (PFS)
Time frame: From the date of treatment initiation up to data cut-off (approximately 24 months)
Overall survival (OS)
Time frame: From the date of treatment initiation up to data cut-off (approximately 24 months)
Plasma pharmacokinetic profile of NMS-03305293 and possible identified metabolites (if appropriate) after oral administration
Time frame: Cycle 1 - Days 1, 2, and 5. Each cycle is 28 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing NMS-03305293 and Topotecan in people with Ovarian Cancer, run by Nerviano Medical Sciences at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Domenico Roberti (+39 0331-581111, clinicaltrials@nervianoms.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Adverse Events (AEs) (time frame: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.